A study on the effectiveness of Indomethacin in preventing post Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis

Phase 4

• Conditions: Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

• Registration Number: ACTRN12613000096752
• Lead Sponsor: Vinh-An Phan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-01-24
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

All patients undergoing Endoscopic Retrograde Cholangiopancreatography

Exclusion Criteria

-Those with active pancreatitis
-Renal impairment
-known allergy to non-steroidal anti-inflammatory drugs (including NSAID induced asthma)
-patients with concomitant NSAID therapy (excluding Aspirin)
-patients without a native papilla
-Active peptic ulcer disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary outcome will be Post-ERCP Pancreatitis, which is defined as:<br>-new-onset abdominal pain<br>-elevation of serum amylase (greater than 3 times the upper limit of normal) after 24 hours<br>-requiring more than 2 days hospitalization[Patients will be observed for 90 minutes post-procedure and then reassessed at the 24 hour mark]

Secondary Outcome Measures

Name	Time	Method
Acute renal impairment (via serum creatinine measurement 24 hours post procedure)[24 hours post procedure]